Novavax (NVAX) Capital Expenditures (2010 - 2026)

Novavax's Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 20.38% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at -$325000.0 (up 91.22% YoY), while the FY2024 annual figure was $1.6 million, down 68.58% from the prior year.
• Capital Expenditures was $1.3 million for Q1 2026 at Novavax, up from -$250000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $19.8 million in Q1 2023 to a low of -$13.2 million in Q2 2023.
• Historically, Capital Expenditures has averaged $1.5 million across 5 years, with a median of $1.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures tumbled 1341.54% in 2023, then surged 350.25% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $12.8 million in 2022, then slumped by 79.33% to $2.6 million in 2023, then tumbled by 461.34% to -$9.5 million in 2024, then soared by 97.38% to -$250000.0 in 2025, then jumped by 608.0% to $1.3 million in 2026.
• The last three Capital Expenditures figures came in at $1.3 million (Q1 2026), -$250000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.